Compare STDN & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STDN | BCRX |
|---|---|---|
| Founded | N/A | 1986 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.1B |
| IPO Year | 2026 | 1995 |
| Metric | STDN | BCRX |
|---|---|---|
| Price | $13.08 | $8.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $20.82 |
| AVG Volume (30 Days) | 823.4K | ★ 3.7M |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 381.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $25,186,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.55 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.05 | $6.00 |
| 52 Week High | $17.34 | $11.22 |
| Indicator | STDN | BCRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.34 | 46.31 |
| Support Level | $11.58 | $8.79 |
| Resistance Level | $13.80 | $9.31 |
| Average True Range (ATR) | 1.07 | 0.32 |
| MACD | -0.19 | -0.02 |
| Stochastic Oscillator | 28.48 | 40.04 |
Standard Nuclear Inc is an independent advanced nuclear fuel company. The company designs, engineers, and manufactures advanced nuclear fuels, with a primary focus on TRISO fuel for advanced reactors. Its operations include industrial-scale TRISO fuel manufacturing and the development of fuel for advanced reactors that utilize TRISO fuel. The company operates in a single operating and reportable segment, as it is engaged in a single business activity of TRISO production. It derives revenue from fuel development and services agreements. Geographically, the maximum revenue is generated from the United States.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.